We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ONCURIOUS NV announces that the European Commission has confirmed the orphan drug designation for TB-403 for medulloblastoma. Today's decision by the EC follows the earlier positive opinion issued by the European Medicine Agency (EMA).
All programs (two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs) have first-in-class and best-in-class potential.
Philips and Illumina announced that they will collaborate to leverage Illumina's sequencing technology and BaseSpace Sequence Hub with Philips' cloud-based IntelliSpace Genomics clinical informatics platform in a bid to advance cancer research.